217 related articles for article (PubMed ID: 37249548)
1. Sustained release ocular drug delivery systems for glaucoma therapy.
Al-Qaysi ZK; Beadham IG; Schwikkard SL; Bear JC; Al-Kinani AA; Alany RG
Expert Opin Drug Deliv; 2023; 20(7):905-919. PubMed ID: 37249548
[TBL] [Abstract][Full Text] [Related]
2. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.
Kompella UB; Hartman RR; Patil MA
Prog Retin Eye Res; 2021 May; 82():100901. PubMed ID: 32891866
[TBL] [Abstract][Full Text] [Related]
3. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation.
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SOA; Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG
Int J Pharm; 2019 Oct; 570():118662. PubMed ID: 31491481
[TBL] [Abstract][Full Text] [Related]
4. [Progression of drug delivery system for glaucoma].
Xu Y; Lyu L
Zhonghua Yan Ke Za Zhi; 2014 Dec; 50(12):946-51. PubMed ID: 25619186
[TBL] [Abstract][Full Text] [Related]
5. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.
Chiang B; Kim YC; Doty AC; Grossniklaus HE; Schwendeman SP; Prausnitz MR
J Control Release; 2016 Apr; 228():48-57. PubMed ID: 26930266
[TBL] [Abstract][Full Text] [Related]
6. Patient Acceptance of Sustained Glaucoma Treatment Strategies.
Varadaraj V; Kahook MY; Ramulu PY; Pitha IF
J Glaucoma; 2018 Apr; 27(4):328-335. PubMed ID: 29462013
[TBL] [Abstract][Full Text] [Related]
7. Sustained drug delivery for glaucoma: current data and future trends.
Aref AA
Curr Opin Ophthalmol; 2017 Mar; 28(2):169-174. PubMed ID: 27764023
[TBL] [Abstract][Full Text] [Related]
8. Novel drug delivery systems for glaucoma.
Lavik E; Kuehn MH; Kwon YH
Eye (Lond); 2011 May; 25(5):578-86. PubMed ID: 21475311
[TBL] [Abstract][Full Text] [Related]
9. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Rodrigues LB; Bravo R; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SO; Cronemberger S; Ferreira AJ; Faraco AA
PLoS One; 2014; 9(4):e95461. PubMed ID: 24788066
[TBL] [Abstract][Full Text] [Related]
10. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.
Belamkar A; Harris A; Zukerman R; Siesky B; Oddone F; Verticchio Vercellin A; Ciulla TA
Ann Med; 2022 Dec; 54(1):343-358. PubMed ID: 35076329
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma.
Fathalla D; Fouad EA; Soliman GM
Drug Dev Ind Pharm; 2020 May; 46(5):806-813. PubMed ID: 32281424
[No Abstract] [Full Text] [Related]
12. Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.
Zhao Y; Huang C; Zhang Z; Hong J; Xu J; Sun X; Sun J
Drug Deliv; 2022 Dec; 29(1):613-623. PubMed ID: 35174743
[TBL] [Abstract][Full Text] [Related]
13. Current and new pharmacotherapeutic approaches for glaucoma.
Shalaby WS; Shankar V; Razeghinejad R; Katz LJ
Expert Opin Pharmacother; 2020 Nov; 21(16):2027-2040. PubMed ID: 32717157
[TBL] [Abstract][Full Text] [Related]
14. Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study.
Rubião F; Araújo ACF; Sancio JB; Nogueira BS; Franca JR; Nogueira JC; Ferreira AJ; Faraco AAG; Foureaux G; Cronemberger S
Curr Drug Deliv; 2021; 18(7):1022-1026. PubMed ID: 33388018
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery.
Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO
J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285
[TBL] [Abstract][Full Text] [Related]
16. Sustained drug delivery in glaucoma.
Knight OJ; Lawrence SD
Curr Opin Ophthalmol; 2014 Mar; 25(2):112-7. PubMed ID: 24463419
[TBL] [Abstract][Full Text] [Related]
17. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.
Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS
PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735
[TBL] [Abstract][Full Text] [Related]
18. Current management of glaucoma.
Lusthaus J; Goldberg I
Med J Aust; 2019 Mar; 210(4):180-187. PubMed ID: 30767238
[TBL] [Abstract][Full Text] [Related]
19. Extended drug delivery by contact lenses for glaucoma therapy.
Peng CC; Burke MT; Carbia BE; Plummer C; Chauhan A
J Control Release; 2012 Aug; 162(1):152-8. PubMed ID: 22721817
[TBL] [Abstract][Full Text] [Related]
20. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO
Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
